Claro Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Claro Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-508	Closed	-$49K	–	245
2018 Q4	$49K	Buy	+508	New	+$48.3K	0.04%	336

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Claro Advisors's BMRN Position: Q1 2019 in Review

Claro Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 508 shares — an estimated $49K sold.

Claro Advisors first reported a position in BMRN in Q4 2018 and held it in 1 quarter. The position peaked at $49K in Q4 2018. 486 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

Claro Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 508 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $49K.
Claro Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Claro Advisors's BioMarin Pharmaceuticals position peaked at $49K in Q4 2018.
486 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.